Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | GHSR | Q92847 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22527034 | 0.91 | PPARA (0.47) | PPARAPPARGCTSSSYKCTSK | |
| SCHEMBL22526120 | 0.89 | REN (0.40) | CTSSRENCTSKATMCA2 | |
| SCHEMBL22526666 | 0.87 | ADRB2 (0.37) | PPARAPPARGCTSSRENCTSK | |
| SCHEMBL22526680 | 0.85 | PPARA (0.47) | PPARAPPARGCTSSRENSYK | |
| SCHEMBL22526869 | 0.84 | PPARA (0.50) | PPARAPPARGCTSSSYKATM | |
| SCHEMBL26236053 | 0.83 | PPARA (0.48) | PPARAPPARGCTSSSYKCTSK | |
| SCHEMBL22525503 | 0.83 | PPARA (0.41) | PPARAPPARGCTSSRENGHSR | |
| SCHEMBL22526440 | 0.82 | REN (0.39) | PPARAPPARGCTSSRENCTSK | |
| SCHEMBL22526435 | 0.82 | REN (0.39) | PPARAPPARGCTSSRENCTSK | |
| SCHEMBL25383208 | 0.81 | HDAC1 (0.40) | PPARAPPARGRENCTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | PPARA 1856/4885PPARG 1830/4885CTSS 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.